\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n\n\n
\n
GRIT<\/h3>\n\n\n\n
Trial Details: Glomerular Disease Registry<\/p>\n\n\n\n
Populations: Glomerular Disease<\/p>\n\n\n\n
PI: Dr Muh Geot Wong<\/p>\n\n\n\n
Sponsor: The George Institute<\/p>\n\n\n\n
PHOSPHATE<\/h3>\n\n\n\n
Trial Details: A Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis<\/p>\n\n\n\n
Populations: Kidney Failure, Chronic Hyperphosphatemia<\/p>\n\n\n\n
PI Dr Emma O\u2019Lone<\/p>\n\n\n\n
Sponsor: The University of Queensland, NHMRC<\/p>\n\n\n\n
TRACK<\/h3>\n\n\n\n
Trial Details: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease<\/p>\n\n\n\n
Populations: Chronic Kidney Diseases, End-Stage Kidney Disease, Cardiovascular Disease<\/p>\n\n\n\n
PI: Dr Muh Geot Wong<\/p>\n\n\n\n
Sponsor: The George Institute<\/p>\n\n\n\n
CARSK<\/h3>\n\n\n\n
Trial Details: Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates Populations<\/p>\n\n\n\n
Populations: Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication<\/p>\n\n\n\n
PI: Dr Stella McGinn<\/p>\n\n\n\n
Sponsor: University of British Columbia<\/p>\n\n\n\n
RESOLVE<\/h3>\n\n\n\n
Trial Details: Randomised Evaluation of Sodium Dialysate Levels on Vascular Events<\/p>\n\n\n\n
Populations: Chronic Kidney Diseases, End-Stage Kidney Disease, Cardiovascular Disease<\/p>\n\n\n\n
PI: Dr Yvonne Shen<\/p>\n\n\n\n
Sponsor: The George Institute<\/p>\n\n\n\n
REDUCCTION<\/h3>\n\n\n\n
Trial Details: Reducing the burden of dialysis Catheter Complications in patients with kidney disease: a National approach<\/p>\n\n\n\n
Populations: End stage kidney disease, Haemodialysis Catheter complications<\/p>\n\n\n\n
PI: Dr MuhGeot Wong<\/p>\n\n\n\n
Sponsor: NHMRC<\/p>\n\n\n\n
TIMELY<\/h3>\n\n\n\n
Trial Details: Treatment modalities for the InfirM ElderLY with end stage kidney disease: the TIMELY study<\/p>\n\n\n\n
Populations: End Stage Renal Disease<\/p>\n\n\n\n
PI: Dr Sarah Roxburgh<\/p>\n\n\n\n
Sponsor: The George Institute, NHRMC Program Grant<\/p>\n\n\n\n
CLARITY<\/h3>\n\n\n\n
Trial Details: Controlled evaluation of Angiotensin Receptor Blockers for COVID-19 respiratory disease<\/p>\n\n\n\n
Populations: End Stage Renal Disease, Cardiovascular disease<\/p>\n\n\n\n
PI: Professor Carol Pollock<\/p>\n\n\n\n
Sponsor: The George Institute <\/p>\n\n\n\n
HaBIT 1<\/h3>\n\n\n\n
Trial Details: Incidence of De novo HLA Antibody formation after Transfusion with blood products in patients with end stage kidney disease who are planned for live donor kidney transplant: A prospective study<\/p>\n\n\n\n
Populations: Live Donor transplant patients at participating hospitals who have a red cell transfusion scheduled.<\/p>\n\n\n\n
PI: Dr Stella McGinn<\/p>\n\n\n\n
Sponsor: Australian Red Cross Blood Service<\/p>\n\n\n\n
TESTING<\/h3>\n\n\n\n
Trial Details: Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) (TESTING)<\/p>\n\n\n\n
Populations: IgA Glomerulonephritis<\/p>\n\n\n\n
PI: Dr Bruce Cooper<\/p>\n\n\n\n
Sponsor: The George Institute<\/p>\n\n\n\n
Teach PD<\/h3>\n\n\n\n
Trial Details: A pragmatic, registry-based, international, cluster-randomised controlled trial examining the use of TEACH-PD training modules for incident PD patients versus existing practices on the rate of PD-related infections<\/p>\n\n\n\n
Populations: CKD, Peritoneal dialysis<\/p>\n\n\n\n
PI: Dr Bruce Cooper<\/p>\n\n\n\n
Sponsor: The University of Queensland acting through Australasian Kidney Trials Network (AKTN)<\/p>\n\n\n\n
CONTEND<\/h3>\n\n\n\n
Trial Details: CONsumer views of Treatment options for Elderly patieNts with kiDney failure<\/p>\n\n\n\n
Populations: CKD, End Stage Kidney Disease<\/p>\n\n\n\n
PI: Dr Sarah Roxburgh<\/p>\n\n\n\n
Sponsor: The George Institute, NHRMC Program Grant<\/p>\n\n\n\n
PREVENA<\/h3>\n\n\n\n
Trial Details: Negative Pressure Wound Therapy (PREVENA) Versus Standard Dressings for Incision Management After Renal Transplant (IMPART)<\/p>\n\n\n\n
Populations: Kidney Transplant, Vascular Surgery<\/p>\n\n\n\n
PI: Dr Vikram Puttaswamy<\/p>\n\n\n\n
Sponsor: Royal North Shore Hospital<\/p>\n\n\n\n
ACHIEVE<\/h3>\n\n\n\n
Trial Details: Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease<\/p>\n\n\n\n
Populations: ESRF, Dialysis patient<\/p>\n\n\n\n
PI: Dr Susan Wan<\/p>\n\n\n\n
Sponsor: Hamilton Health Sciences<\/p>\n\n\n\n
AlIGNI<\/h3>\n\n\n\n
Trial Details: A Phase 3, Randomized, Double-blind, Placebocontrolled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)<\/p>\n\n\n\n
Populations: IgA Nephropathy<\/p>\n\n\n\n
PI: Dr Muh Geot Wong<\/p>\n\n\n\n
Sponsor: Chinook Therapeutics<\/p>\n\n\n\n
AFFINITY<\/h3>\n\n\n\n
Trial Details: The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.<\/p>\n\n\n\n
Populations: IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease<\/p>\n\n\n\n
PI: Dr Muh Geot Wong<\/p>\n\n\n\n
Sponsor: Chinook Therapeutics<\/p>\n\n\n\n
FLOW<\/h3>\n\n\n\n
Trial Details: Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease<\/p>\n\n\n\n
Populations: Diabetes Mellitus, Type 2<\/p>\n\n\n\n
PI: Dr Muh Geot Wong<\/p>\n\n\n\n
Sponsor: Novo Nordisk<\/p>\n\n\n\n
DUPLEX<\/h3>\n\n\n\n
Trial Details: A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS<\/p>\n\n\n\n
Populations: Focal Segmental Glomerulosclerosis<\/p>\n\n\n\n
PI: Dr Muh Geot Wong<\/p>\n\n\n\n
Sponsor: Retrophin, Inc.<\/p>\n\n\n\n
PROTECT<\/h3>\n\n\n\n
Trial Details: A randomized, multicenter, double-blind, parallel-group, active-control study of the efficacy and safety of sparsentan for the treatment of immunoglobulin A nephropathy<\/p>\n\n\n\n
Populations: Immunoglobulin A Nephropathy<\/p>\n\n\n\n
PI: Dr Muh Geot Wong<\/p>\n\n\n\n
Sponsor: Retrophin, Inc.<\/p>\n\n\n\n
IONIS<\/h3>\n\n\n\n
Trial Details: An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA Nephropathy<\/p>\n\n\n\n
Populations: Primary IgA Nephropathy<\/p>\n\n\n\n
PI: Dr Muh Geot Wong<\/p>\n\n\n\n
Sponsor: Ionis Pharmaceuticals, Inc. <\/p>\n\n\n\n
ENVISION VIS649 (Previously called VISTERRA)<\/h3>\n\n\n\n
Trial Details: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy<\/p>\n\n\n\n
Populations: IgA Disease<\/p>\n\n\n\n
PI: Dr MuhGeot Wong<\/p>\n\n\n\n
Sponsor: Visterra, Inc<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n","protected":false},"featured_media":418,"template":"","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","footnotes":""},"research-group-tax":[],"primary-research-area":[58],"class_list":["post-2676","research-group","type-research-group","status-publish","has-post-thumbnail","hentry","primary-research-area-cardiovascular-and-renal"],"acf":{"team_leads":"","team_members":[3186,3498,3187,3524,3525,3526,3527,3528,3529]},"uagb_featured_image_src":{"full":["https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/07\/root_Banners_Renal-Clinical-Trials-banner-scaled.jpg",2560,825,false],"thumbnail":["https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/07\/root_Banners_Renal-Clinical-Trials-banner-150x150.jpg",150,150,true],"medium":["https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/07\/root_Banners_Renal-Clinical-Trials-banner-300x97.jpg",300,97,true],"medium_large":["https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/07\/root_Banners_Renal-Clinical-Trials-banner-768x247.jpg",768,247,true],"large":["https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/07\/root_Banners_Renal-Clinical-Trials-banner-1024x330.jpg",1024,330,true],"1536x1536":["https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/07\/root_Banners_Renal-Clinical-Trials-banner-1536x495.jpg",1536,495,true],"2048x2048":["https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/07\/root_Banners_Renal-Clinical-Trials-banner-2048x660.jpg",2048,660,true]},"uagb_author_info":{"display_name":"ict-wordpress-support@sydney.edu.au","author_link":"https:\/\/kollinginstitute.org.au\/news_demo\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"The Royal North Shore Hospital Renal Clinical Trial Unit has a strong research history, participating in Phase 2 to Phase 4 clinical research for more than 20 years. We have a high performing, research-oriented unit, working to deliver best-practice healthcare and overall community wellbeing. With a strong focus on collaboration, our unit works closely with…","_links":{"self":[{"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/research-group\/2676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/research-group"}],"about":[{"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/types\/research-group"}],"version-history":[{"count":1,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/research-group\/2676\/revisions"}],"predecessor-version":[{"id":4964,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/research-group\/2676\/revisions\/4964"}],"acf:post":[{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3529"},{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3528"},{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3527"},{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3526"},{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3525"},{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3524"},{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3187"},{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3498"},{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/team-members\/3186"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/media\/418"}],"wp:attachment":[{"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/media?parent=2676"}],"wp:term":[{"taxonomy":"research-group-tax","embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/research-group-tax?post=2676"},{"taxonomy":"primary-research-area","embeddable":true,"href":"https:\/\/kollinginstitute.org.au\/news_demo\/wp-json\/wp\/v2\/primary-research-area?post=2676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/08\/Icons_lead-icon2.png\"){kind=icon}
<\/figure>\n\n\n\n![\"\"](\"https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/08\/Icons_people-icon2.png\"){kind=icon}
<\/figure>\n\n\n\n![\"\"](\"https:\/\/kollinginstitute.org.au\/news_demo\/wp-content\/uploads\/2025\/08\/Icons_projects-icon2.png\"){kind=icon}
<\/figure>\n\n\n\n